Literature DB >> 15053456

Ten-year radiographic outcome in patients with rheumatoid factor positive rheumatoid arthritis treated with aggressive immunosuppressive combination therapy.

John Darmawan1, Johannes J Rasker, Hendri Nuralim.   

Abstract

We observed 10-year radiographic outcomes in patients with rheumatoid factor positive rheumatoid arthritis prospectively. Group I, II, and III comprised 87, 125, and 89 consecutive subjects with disease duration at presentation of less than 4, 4-24, and 25-255 months, respectively. Initial therapy was with combinations of pulse intravenous (i.v.) methylprednisolone (0-125 mg), cyclophosphamide (100-200 mg), methotrexate (MTX, 5-15 i.v. mg/week) and simultaneous oral cyclosporin A (CSA, 25 mg bid/tid). After disease was controlled i.v. therapy was tapered and switched to oral MTX + CSA. Outcomes from the Larsen Index and Erosive Joint Count were compared in cases and in dropouts with baseline and each other. Significant improvement in the Larsen Index and Erosive Joint Count was observed in Group I (p < 0.0001). In Group II and III the improvement or deterioration was not significant. The Larsen Index and Erosive Joint Count deteriorated significantly in the dropouts compared with baseline and cases (p < 0.0001). In conclusion, in early RA, in a Malayo-Polynesian patient sample, radiological progression could be halted with aggressive combination treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15053456

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  2 in total

Review 1.  Successfully living with chronic arthritis. The role of the allied health professionals.

Authors:  Erik Taal; Elzbieta Bobietinska; Jill Lloyd; Martine Veehof; Wietske Jm Rasker; F G J Frits Oosterveld; J J Hans Rasker
Journal:  Clin Rheumatol       Date:  2005-07-12       Impact factor: 2.980

Review 2.  Recommendations from the Community Oriented Program for Control of Rheumatic Disease for data collection for the measurement and monitoring of health in developing countries.

Authors:  John Darmawan
Journal:  Clin Rheumatol       Date:  2007-03-16       Impact factor: 3.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.